Tempest Therapeutics, Inc. (TPST) |
|
2.32 -0.59 (-20.27%)
|
03-31 16:00 |
|
Open: |
2.97 |
Pre. Close: |
2.91 |
|
High:
|
3.23 |
Low:
|
2.2801 |
|
Volume:
|
126,179 |
Market Cap:
|
33(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:22:39 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.77  One year: 4.4 |
| Support: |
Support1: 1.88 Support2: 1.05 |
| Resistance: |
Resistance1: 3.23 Resistance2: 3.77 |
| Pivot: |
1.57 |
| Moving Average: |
MA(5): 2.15 MA(20): 1.54
MA(100): 1.62 MA(250): 2.12 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 81.6 %D(3): 87.2 |
| RSI: |
RSI(14): 63.3 |
| 52-week: |
High: 4.42 Low: 1.05 |
| Average Vol(K): |
3-Month: 24 (K) 10-Days: 61 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TPST ] has closed below upper band by 13.2%. Bollinger Bands are 262.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.23 - 3.25 |
3.25 - 3.26 |
|
Low:
|
2.25 - 2.27 |
2.27 - 2.28 |
|
Close:
|
2.3 - 2.32 |
2.32 - 2.34 |
|
Company Description |
|
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc. |
Headline News |
Fri, 31 Mar 2023
Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Friday? - InvestorsObserver
Wed, 29 Mar 2023
Healthcare Stocks Moving Wednesday: TPST, RNXT, ARCT, CFMS, PRQR, SHCR, PIRS, BLUE - InvestorsObserver
Wed, 29 Mar 2023
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are ... - Investing.com UK
Wed, 15 Mar 2023
Tempest to Present Biomarker Data for TPST-1120 at the Society for ... - GlobeNewswire
Tue, 08 Nov 2022
Tempest Reports Third Quarter 2022 Financial Results and Provides ... - GlobeNewswire
Thu, 26 May 2022
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
11 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
3.2 (%) |
|
% Held by Institutions
|
71.2 (%) |
|
Shares Short
|
30 (K) |
|
Shares Short P.Month
|
17 (K) |
Stock Financials |
|
EPS
|
-9.29 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
6.3 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-29.9 |
|
Return on Equity (ttm)
|
-97.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.92 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-33 (M) |
|
Levered Free Cash Flow
|
-18 (M) |
Stock Valuations |
|
PE Ratio
|
-0.25 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.36 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.75 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-12-09 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
